These results are consistent with our previous findings in pancreatic cancer (Wang et al., 2018) and HCC (Wang et al., 2019c) models, demonstrating that MA242's MDM2-targeting activity is consistent across various cancer types. This evidence concerns the gene MDM2 and familial pancreatic carcinoma.